mitoxantrone has been researched along with Febrile Neutropenia in 2 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Remission induction regimens for acute lymphoblastic leukemia (ALL) in adults induce complete remission (CR) in 60-90% and cure in 20-40%." | 1.42 | Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience. ( Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Herrera-Garza, JL; Jaime-Perez, JC; Pinzón-Uresti, MA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, S | 1 |
| Suciu, S | 1 |
| Stasi, R | 1 |
| Salih, HR | 1 |
| Selleslag, D | 1 |
| Muus, P | 1 |
| De Fabritiis, P | 1 |
| Venditti, A | 1 |
| Ho, AD | 1 |
| Lübbert, M | 1 |
| Thomas, X | 1 |
| Latagliata, R | 1 |
| Halkes, CJ | 1 |
| Falzetti, F | 1 |
| Magro, D | 1 |
| Guimaraes, JE | 1 |
| Berneman, Z | 1 |
| Specchia, G | 1 |
| Karrasch, M | 1 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Willemze, R | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Jaime-Perez, JC | 1 |
| Colunga-Pedraza, PR | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Pinzón-Uresti, MA | 1 |
| Cantú-Rodríguez, OG | 1 |
| Herrera-Garza, JL | 1 |
| Gómez-Almaguer, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC[NCT00052299] | Phase 3 | 472 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mitoxantrone and Febrile Neutropenia
| Article | Year |
|---|---|
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
1 other study available for mitoxantrone and Febrile Neutropenia
| Article | Year |
|---|---|
Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Cohort Studies; Disease-Free Surviva | 2015 |